Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO is a pharmaceutical importer based in the Netherlands, specializing in the procurement of finished pharmaceutical formulations from India. The company operates as a buyer, sourcing a range of pharmaceutical products to meet the demands of the Dutch market. While specific details about its headquarters and parent company are not publicly available, its role in the Netherlands pharmaceutical distribution network is significant, focusing on the importation and distribution of generic medications.

The distribution network specifics of Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO are not publicly disclosed. However, given the company's focus on importing finished pharmaceutical formulations from India, it is likely that it collaborates with established logistics providers to ensure efficient delivery within the Netherlands. The Netherlands' strategic location and advanced logistics infrastructure, including proximity to major ports and airports, facilitate the efficient distribution of pharmaceutical products throughout the country.

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO functions primarily as a pharmaceutical importer, sourcing finished pharmaceutical formulations from India. Its role in the Netherlands pharmaceutical supply chain involves importing generic medications to meet domestic demand. The company's focus on finished formulations indicates a specialization in the distribution of ready-to-use pharmaceutical products, catering to various therapeutic areas.

The company's sourcing strategy reveals a high concentration on a single supplier, MYLAN LABORATORIES LIMITED, which accounts for 100% of its imports from India. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or quality control issues. However, the consistent volume of shipments and the substantial total import value suggest a stable and long-term relationship between Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO and MYLAN LABORATORIES LIMITED. The company's portfolio concentration, with the top five products comprising 100% of its imports, further indicates a focused sourcing approach.

The resilience of Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO's supply chain is closely tied to its exclusive reliance on MYLAN LABORATORIES LIMITED. This singular sourcing strategy may limit the company's ability to mitigate risks associated with supply chain disruptions. The lack of publicly available information on backup suppliers and formulation diversity suggests potential vulnerabilities. Additionally, the company's exposure to specific shipping routes and its compliance with regulatory standards are not detailed, which are critical factors in assessing overall supply chain resilience.

The concentrated sourcing pattern of Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO positions it as a significant buyer for MYLAN LABORATORIES LIMITED, potentially securing favorable terms and priority in supply. For Indian exporters, this presents an opportunity to establish a direct relationship with a key importer in the Netherlands, potentially expanding their market reach. However, the lack of diversification in the company's supplier base may limit opportunities for other Indian exporters to penetrate this specific channel.

In the Netherlands, the Medicines Evaluation Board (MEB) is the primary regulatory authority overseeing the authorization and supervision of medicinal products. The Medicines Act (Geneesmiddelenwet) serves as the key legislation governing pharmaceutical imports, ensuring that all medicinal products meet safety, efficacy, and quality standards. For Indian generics, obtaining a marketing authorization from the MEB is essential for entry into the Dutch market. This process involves demonstrating that the generic product is interchangeable with the Dutch reference medicinal product, ensuring no differences in efficacy and safety. (english.cbg-meb.nl)

Importers of medicinal products into the Netherlands must obtain a pharmaceutical permit from the Dutch Ministry of Health, Welfare, and Sport (VWS). This permit is mandatory for entities involved in the wholesale or packaging of medicines. Additionally, imported pharmaceutical products must comply with Good Manufacturing Practice (GMP) standards. The MEB recognizes GMP certificates from the European Union (EU GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers are required to ensure that their suppliers hold valid GMP certifications from these recognized bodies to maintain compliance with Dutch regulations. (business.gov.nl)

Imported pharmaceutical products must undergo batch testing to verify their quality and compliance with Dutch standards. Stability requirements are enforced to ensure that products maintain their efficacy and safety throughout their shelf life. Labeling must be in Dutch, providing clear and accurate information to consumers and healthcare professionals. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market. These regulations are designed to uphold the integrity of the pharmaceutical supply chain and protect public health. (business.gov.nl)

Between 2024 and 2026, the Netherlands has implemented several policy changes affecting pharmaceutical imports. Notably, the introduction of the Carbon Border Adjustment Mechanism (CBAM) Regulation requires importers of carbon-intensive products to obtain authorization, submit CBAM declarations, and pay for the CO₂ emitted during production. This regulation aims to align import practices with environmental sustainability goals. Additionally, the Medicines Evaluation Board (MEB) has updated procedures for parallel imports, emphasizing the need for a marketing authorization for parallel import products. These changes impact how Indian generics are imported and marketed in the Netherlands. (business.gov.nl)

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO's product strategy focuses on therapeutic areas with high demand in the Netherlands. The company's imports are predominantly in the Diabetes & Endocrine category (69.9%), followed by Lipid & Metabolism (24.5%), and Cardiovascular (5.6%). This focus aligns with the growing prevalence of lifestyle-related diseases in the Netherlands, such as diabetes and cardiovascular conditions. The substantial import value of Sitagliptin ($1.2M) and Febuxostat ($414K) indicates a strategic emphasis on these high-demand medications.

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO's sourcing strategy is centered on generic drugs, primarily sourced from India. The company's preference for finished pharmaceutical formulations suggests a focus on ready-to-use products that meet Dutch regulatory standards. India's robust pharmaceutical manufacturing sector, with its adherence to international GMP standards, makes it a reliable source for these products. The company's exclusive reliance on MYLAN LABORATORIES LIMITED for its imports indicates a strategic partnership aimed at ensuring consistent quality and supply.

Based on its product mix, Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO serves the wholesale distribution segment of the Netherlands market. By importing and distributing generic medications, the company plays a crucial role in making affordable pharmaceutical products accessible to various healthcare providers, including hospitals, clinics, and pharmacies. Its focus on high-demand therapeutic areas positions it as a key player in addressing prevalent health concerns within the Dutch population.

For new Indian suppliers, there is a realistic opportunity to engage with Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO, given the company's exclusive reliance on MYLAN LABORATORIES LIMITED. Introducing alternative suppliers could provide the company with options to diversify its sourcing and mitigate potential supply chain risks. However, the company's concentrated product portfolio, with the top five products comprising 100% of its imports, suggests that any new supplier would need to offer products that align with the company's existing therapeutic focus.

Indian exporters aiming to supply Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO and the broader Netherlands market must ensure compliance with Dutch and EU regulations. This includes obtaining marketing authorizations from the Medicines Evaluation Board (MEB) and ensuring that products meet Dutch safety, efficacy, and quality standards. Additionally, products must comply with Good Manufacturing Practice (GMP) standards recognized by the MEB, such as EU GMP, WHO GMP, or PIC/S certifications. Proper labeling in Dutch and adherence to serialization mandates are also essential. (english.cbg-meb.nl)

To establish a relationship with Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO, Indian exporters should first ensure that their products meet all regulatory requirements for the Netherlands market. This includes obtaining the necessary marketing authorizations and GMP certifications.